Gast ::
| Hauptseite > Publikationsdatenbank > Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide > print |
| Hauptseite > Publikationsdatenbank > Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide > print |
| 001 | 60107 | ||
| 005 | 20200402210439.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:17606418 |
| 024 | 7 | _ | |2 DOI |a 10.1016/j.jchromb.2007.06.003 |
| 024 | 7 | _ | |2 WOS |a WOS:000249615100032 |
| 037 | _ | _ | |a PreJuSER-60107 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 540 |
| 084 | _ | _ | |2 WoS |a Biochemical Research Methods |
| 084 | _ | _ | |2 WoS |a Chemistry, Analytical |
| 100 | 1 | _ | |a Wiesehan, K. |b 0 |u FZJ |0 P:(DE-Juel1)VDB15437 |
| 245 | _ | _ | |a Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide |
| 260 | _ | _ | |a New York, NY [u.a.] |b Science Direct |c 2007 |
| 300 | _ | _ | |a 229 - 233 |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |a Journal of Chromatography B |x 1570-0232 |0 3155 |v 856 |
| 500 | _ | _ | |a Record converted from VDB: 12.11.2012 |
| 520 | _ | _ | |a The amyloid cascade hypothesis assigns the amyloid-beta peptide (Abeta) a central role in the pathogenesis of Alzheimer's disease (AD). Although there are strong efforts to biophysically characterize formation of Abeta aggregates and fibrils, as well as their prevention, progress is still severly hampered by the availability of tens of milligrams of recombinant Abeta(1-42). Here, we describe a reliable and easy procedure to recombinantly express and purify Abeta(1-42), which is fully cytotoxic and able to form fibrils without any further refolding steps. The yield of the procedure is 5-8 mg of tag-less peptide per liter culture volume. |
| 536 | _ | _ | |a Funktion und Dysfunktion des Nervensystems |c P33 |2 G:(DE-HGF) |0 G:(DE-Juel1)FUEK409 |x 0 |
| 588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
| 650 | _ | 2 | |2 MeSH |a Amino Acid Sequence |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: isolation & purification |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: pharmacology |
| 650 | _ | 2 | |2 MeSH |a Base Sequence |
| 650 | _ | 2 | |2 MeSH |a Chromatography, High Pressure Liquid |
| 650 | _ | 2 | |2 MeSH |a DNA Primers |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Molecular Sequence Data |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: isolation & purification |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: pharmacology |
| 650 | _ | 2 | |2 MeSH |a Recombinant Proteins: isolation & purification |
| 650 | _ | 2 | |2 MeSH |a Recombinant Proteins: pharmacology |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Amyloid beta-Peptides |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a DNA Primers |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Peptide Fragments |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Recombinant Proteins |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a amyloid beta-protein (1-42) |
| 650 | _ | 7 | |a J |2 WoSType |
| 653 | 2 | 0 | |2 Author |a purification |
| 653 | 2 | 0 | |2 Author |a amyloid-beta peptide |
| 653 | 2 | 0 | |2 Author |a cytotoxicity |
| 653 | 2 | 0 | |2 Author |a aggregation |
| 653 | 2 | 0 | |2 Author |a Alzheimer's disease |
| 700 | 1 | _ | |a Funke, S. A. |b 1 |u FZJ |0 P:(DE-Juel1)VDB65869 |
| 700 | 1 | _ | |a Fries, M. |b 2 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Willbold, D. |b 3 |u FZJ |0 P:(DE-Juel1)132029 |
| 773 | _ | _ | |a 10.1016/j.jchromb.2007.06.003 |g Vol. 856, p. 229 - 233 |p 229 - 233 |q 856<229 - 233 |0 PERI:(DE-600)1491259-4 |t Journal of chromatography / B |v 856 |y 2007 |x 1570-0232 |
| 856 | 7 | _ | |u http://dx.doi.org/10.1016/j.jchromb.2007.06.003 |
| 909 | C | O | |o oai:juser.fz-juelich.de:60107 |p VDB |
| 913 | 1 | _ | |k P33 |v Funktion und Dysfunktion des Nervensystems |l Funktion und Dysfunktion des Nervensystems |b Gesundheit |0 G:(DE-Juel1)FUEK409 |x 0 |
| 914 | 1 | _ | |y 2007 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed |
| 920 | 1 | _ | |k INB-2 |l Molekulare Biophysik |d 31.12.2008 |g INB |0 I:(DE-Juel1)VDB805 |x 0 |
| 920 | 1 | _ | |k JARA-SIM |l Jülich-Aachen Research Alliance - Simulation Sciences |g JARA |0 I:(DE-Juel1)VDB1045 |x 1 |
| 970 | _ | _ | |a VDB:(DE-Juel1)94303 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)ISB-2-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)VDB1045 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 981 | _ | _ | |a I:(DE-Juel1)ISB-2-20090406 |
| 981 | _ | _ | |a I:(DE-Juel1)VDB1045 |
| 981 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|